Crispr-Based Drug Development Platforms Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY PRODUCT

1. 5.1. Introduction

2. 5.2. CRISPR Libraries

3. 5.3. CRISPR Kits & Reagents

4. 5.4. CRISPR Enzymes (Cas Proteins)

5. 5.5. Guide RNA (gRNA) Design Tools

6. 5.6. Delivery Systems

7. 5.7. Cell Lines & Engineering Services

8. 5.8. Software & Bioinformatics Platforms

6. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. CRISPR-Cas9

3. 6.3. CRISPR-Cas12

4. 6.4. CRISPR-Cas13

5. 6.5. Base Editing

6. 6.6. Prime Editing

7. 6.7. Epigenome Editing

7. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Drug Discovery & Development

3. 7.3. Functional Genomics

4. 7.4. Disease Modeling

5. 7.5. Target Identification & Validation

6. 7.6. Cell Line Engineering

8. CRISPR-BASED DRUG DEVELOPMENT PLATFORMS MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. CRISPR Therapeutics

2. 10.2. Intellia Therapeutics

3. 10.3. Editas Medicine

4. 10.4. Beam Therapeutics

5. 10.5. Mammoth Biosciences

6. 10.6. Caribou Biosciences

7. 10.7. Synthego

8. 10.8. Lonza Group

9. 10.9. Thermo Fisher Scientific

10. 10.10. Merck KGaA

11. 10.11. Takara Bio Inc.

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations